Sanofi SA
SNYNF
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
E: investor.relations@sanofi.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
74,846
Sanofi SA News & Analysis
markets
Globalisation declining? Not in investor portfolios
Morningstar Indexes through a geographic revenue lens.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,004.70 | 38.80 | -0.43% |
| CAC 40 | 8,516.20 | 36.33 | 0.43% |
| DAX 40 | 25,718.15 | 99.74 | -0.39% |
| Dow JONES (US) | 53,055.91 | 155.84 | 0.29% |
| FTSE 100 | 10,703.80 | 52.03 | 0.49% |
| HKSE | 23,496.89 | 119.43 | -0.51% |
| NASDAQ | 26,121.16 | 288.49 | 1.12% |
| Nikkei 225 | 68,256.96 | 1,480.73 | -2.12% |
| NZX 50 Index | 13,762.79 | 0.31 | -0.00% |
| S&P 500 | 7,537.43 | 54.19 | 0.72% |
| S&P/ASX 200 | 8,803.90 | 35.50 | -0.40% |
| SSE Composite Index | 3,990.24 | 51.00 | -1.26% |